文献速递认知障碍与痴呆

比较组水平与个体化脑区在测量阿尔茨海默病纵向tau正电子发射断层扫描变化中的差异

Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
PubMed 文献 · JAMA Neurol · 2023-01-01

该纵向队列研究纳入BioFINDER-2中215名不同临床阶段参与者及验证样本,比较组水平与个体化感兴趣区(ROI)在tau-PET年百分比变化和样本量需求上的差异。结果显示,某些个体化ROI较组水平ROI可提高效应量并降低样本量需求。

要点

  • 在Aβ阳性认知未受损个体中,组水平ROI的tau-PET SUVR年百分比增幅最大为4.29%(95%CI 3.42%-5.16%)。
  • 在Aβ阳性轻度认知障碍个体中,最大变化见于颞叶皮层区域(5.82%;95%CI 4.67%-6.97%)。
  • 在阿尔茨海默病痴呆个体中,最大变化见于顶叶区域(5.22%;95%CI 3.95%-6.49%)。

核心结论

  • 某些个体化ROI在评估纵向tau变化方面优于组水平ROI,并可提高以纵向tau PET为结局的阿尔茨海默病临床试验检测治疗效应的把握度。

研究设计与样本

  • 纵向队列研究,连续入组时间为2017年9月18日至2021年11月15日,纳入瑞典BioFINDER-2研究中Aβ阳性认知未受损、Aβ阳性轻度认知障碍和阿尔茨海默病痴呆参与者共215名,并纳入验证样本。

主要发现

  • BioFINDER-2共纳入215名参与者,平均(标准差)年龄71.4(7.5)岁,男性111名(51.6%);其中Aβ阳性认知未受损97名、Aβ阳性轻度认知障碍77名、阿尔茨海默病痴呆41名。
  • 平均(标准差)随访时间为1.8(0.3)年。
  • 使用组水平ROI时,Aβ阳性认知未受损个体中tau-PET SUVR年百分比增幅最大见于内嗅皮层、海马和杏仁核复合ROI(4.29%;95%CI 3.42%-5.16%)。
  • Aβ阳性轻度认知障碍个体中最大变化见于颞叶皮层区域(5.82%;95%CI 4.67%-6.97%),阿尔茨海默病痴呆个体中最大变化见于顶叶区域(5.22%;95%CI 3.95%-6.49%)。
  • 多个个体化ROI的年百分比变化估计值显著更高;最简单的个体化方法(在与参与者数据驱动疾病阶段最匹配的ROI中计算tau PET变化)在全部3个亚组中表现最佳。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Longitudinal tau positron emission tomography (PET) is a relevant outcome in clinical trials evaluating disease-modifying therapies in Alzheimer disease (AD). A key unanswered question is whether the use of participant-specific (individualized) regions of interest (ROIs) is superior to conventional approaches where the same ROI (group-level) is used for each participant. OBJECTIVE: To compare group- and participant-level ROIs in participants at different stages of the AD clinical continuum in terms of annual percentage change in tau-PET standardized uptake value ratio (SUVR) and sample size requirements. DESIGN, SETTING, AND PARTICIPANTS: This was a longitudinal cohort study with consecutive participant enrollment between September 18, 2017, and November 15, 2021. Included in the analysis were participants with mild cognitive impairment and AD dementia from the prospective and longitudinal Swedish Biomarkers For Identifying Neurodegenerative Disorders Early and Reliably 2 (BioFINDER-2) study; in addition, a validation sample (the AVID 05e, Expedition-3, Alzheimer's Disease Neuroimaging Initiative [ADNI], and BioFINDER-1 study cohorts) was also included. EXPOSURES: Tau PET (BioFINDER-2, [18F]RO948; validation sample, [18F]flortaucipir), 7 group-level (5 data-driven stages, meta-temporal, whole brain), and 5 individualized ROIs. MAIN OUTCOMES AND MEASURES: Annual percentage change in tau-PET SUVR across ROIs. Sample size requirements in simulated clinical trials using tau PET as an outcome were also calculated. RESULTS: A total of 215 participants (mean [SD] age, 71.4 (7.5) years; 111 male [51.6%]) from the BioFINDER-2 study were included in this analysis: 97 amyloid-β (Aβ)-positive cognitively unimpaired (CU) individuals, 77 with Aβ-positive mild cognitive impairment (MCI), and 41 with AD dementia. In the validation sample were 137 Aβ-positive CU participants, 144 with Aβ-positive MCI, and 125 with AD dementia. Mean (SD) follow-up time was 1.8 (0.3) years. Using group-level ROIs, the largest annual percentage increase in tau-PET SUVR in Aβ-positive CU individuals was seen in a composite ROI combining the entorhinal cortex, hippocampus, and amygdala (4.29%; 95% CI, 3.42%-5.16%). In individuals with Aβ-positive MCI, the greatest change was seen in the temporal cortical regions (5.82%; 95% CI, 4.67%-6.97%), whereas in those with AD dementia, the greatest change was seen in the parietal regions (5.22%; 95% CI, 3.95%-6.49%). Significantly higher estimates of annual percentage change were found using several of the participant-specific ROIs. Importantly, the simplest participant-specific approach, where change in tau PET was calculated in an ROI that best matched the participant's data-driven disease stage, performed best in all 3 subgroups. For the power analysis, sample size reductions for the participant-specific ROIs ranged from 15.94% (95% CI, 8.14%-23.74%) to 72.10% (95% CI, 67.10%-77.20%) compared with the best-performing group-level ROIs. Findings were replicated using [18F]flortaucipir. CONCLUSIONS AND RELEVANCE: Finding suggest that certain individualized ROIs carry an advantage over group-level ROIs for assessing longitudinal tau changes and increase the power to detect treatment effects in AD clinical trials using longitudinal tau PET as an outcome.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Leuzy A, Binette AP, Vogel JW, et al. Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA Neurol. 2023. PMID: 37155176. doi:10.1001/jamaneurol.2023.1067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。